Clinical trial
Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast…
NCT00334802 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00334802 |
|---|---|
| Title | Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer |
| Official title | Combination Study of LY188011 and Paclitaxel in Patients With Metastatic/Recurrent Breast Cancer After Neo-adjuvant/Adjuvant Chemotherapy With Anthracycline |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine, paclitaxel |
| Enrollment | 62 |
| Start date | Jun 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Mar 1, 2010 |
| First posted | Jun 8, 2006 |
| Last update posted | Mar 16, 2010 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: